[HTML][HTML] Recent developments in anticancer kinase inhibitors based on the pyrazolo [3, 4-d] pyrimidine scaffold
DJ Baillache, A Unciti-Broceta - RSC medicinal chemistry, 2020 - pubs.rsc.org
Pyrazolo [3, 4-d] pyrimidines have become of significant interest for the medicinal chemistry
community as a privileged scaffold for the development of kinase inhibitors to treat a range …
community as a privileged scaffold for the development of kinase inhibitors to treat a range …
[HTML][HTML] Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases
JCH Yang, M Schuler, S Popat, S Miura… - Journal of Thoracic …, 2020 - Elsevier
Introduction Limited clinical data are available regarding the efficacy of EGFR tyrosine
kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR …
kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR …
[HTML][HTML] Management of brain and leptomeningeal metastases from breast cancer
A Pellerino, V Internò, F Mo, F Franchino… - International Journal of …, 2020 - mdpi.com
The management of breast cancer (BC) has rapidly evolved in the last 20 years. The
improvement of systemic therapy allows a remarkable control of extracranial disease …
improvement of systemic therapy allows a remarkable control of extracranial disease …
Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer
N Magios, F Bozorgmehr, AL Volckmar… - Therapeutic …, 2021 - journals.sagepub.com
Background: Epidermal growth factor receptor-mutated (EGFR+) non-small-cell lung cancer
(NSCLC) patients failing tyrosine kinase inhibitors (TKI) can benefit from next-line targeted …
(NSCLC) patients failing tyrosine kinase inhibitors (TKI) can benefit from next-line targeted …
[HTML][HTML] Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort …
CE Wu, CF Chang, CY Huang, CT Yang, CHS Kuo… - BMC cancer, 2021 - Springer
Background Afatinib is one of the standard treatments for patients with epidermal growth
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
[HTML][HTML] Molecularly Targeted Photothermal Ablation of Epidermal Growth Factor Receptor-Expressing Cancer Cells with a Polypyrrole–Iron Oxide–Afatinib …
Simple Summary In this manuscript, we describe the design and synthesis of a
nanocomposite containing afatinib, polypyrrole, and iron oxide (PIA-NC) to molecularly …
nanocomposite containing afatinib, polypyrrole, and iron oxide (PIA-NC) to molecularly …
[HTML][HTML] Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b …
F de Marinis, KK Laktionov, A Poltoratskiy, I Egorova… - Lung Cancer, 2021 - Elsevier
Objectives Randomized controlled trials have demonstrated that afatinib is a suitable
treatment option for patients with epidermal growth factor receptor mutation-positive …
treatment option for patients with epidermal growth factor receptor mutation-positive …
[HTML][HTML] Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial
F Saran, L Welsh, A James, C McBain… - Journal of Neuro …, 2021 - Springer
Background Glioblastoma multiforme (GBM) is the most common primary malignant brain
tumor in adults. Amplification or overexpression of the epidermal growth factor receptor …
tumor in adults. Amplification or overexpression of the epidermal growth factor receptor …
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice
WM Brückl, M Reck, F Griesinger… - Therapeutic …, 2021 - journals.sagepub.com
Background: Lung cancer is a leading cause of cancer-related death in Germany and
worldwide. Non-small cell lung cancer (NSCLC) comprises~ 80% of lung cancer diagnoses; …
worldwide. Non-small cell lung cancer (NSCLC) comprises~ 80% of lung cancer diagnoses; …
[HTML][HTML] Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
SY Lee, CM Choi, YS Chang, KY Lee… - … lung cancer Research, 2021 - ncbi.nlm.nih.gov
Background We investigated the clinical characteristics and treatment outcomes of Korean
patients receiving first-line afatinib for advanced epidermal growth factor receptor mutation …
patients receiving first-line afatinib for advanced epidermal growth factor receptor mutation …